Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Thromb Haemost 1991; 65(01): 110
DOI: 10.1055/s-0038-1647464
DOI: 10.1055/s-0038-1647464
Letter to the Editor
Portal Vein Thrombosis Repermeabilization with rt-PA
Further Information
Publication History
Received 10 July 1990
Accepted after revision 28 August 1990
Publication Date:
02 July 2018 (online)
-
References
- 1 Bergmann SR, Fox K AA, Ter-Pogossian MM, Sobel BE. Clotselective coronary thrombolysis with tissue-type plasminogen activator. Science 1983; 220: 1181-1183
- 2 Tiefenbrunn AJ, Robison AK, Kurnik PB, Ludbrook PA, Sobel BE. Clinical pharmacology in patients with evolving myocardial infarction of tissue-type plasminogen activator produced by recombinant DNA technology. Circulation 1985; 71: 110-116
- 3 Van de WerfE, Bergmann SR, Fox K AA, De Geest H, Hoyng CE, Sobel BE, Collen D. Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology. Circulation 1984; 69: 605-610
- 4 Jaffe AS, Sobel BE. Thrombolysis with tissue-type plasminogen activator in acute myocardial infarction. Jama 1986; 255: 237-239
- 5 Verstraete M, Bounameaux H, De Cock R, Van De WerfE, Collen D. Pharmocokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) itt humans. J Pharmacol Exp Ther 1985; 235: 506-512
- 6 Angelli G, Buchanan MR, Fernandez E, Van Ryn J, Hirsh J. Sustained thrombolysis with DNA-recombinant tissue-type plasminogen activator in rabbits. Blood 1985; 66: 399-401
- 7 Matsuo O, Rijken DC, Collen D. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinease in vitro. Thromb Haemostas 1981; 45: 225-229